Latest research about active pharmaceutical ingredient loaded Poly Lactic Acid-co-Glycolic Acid (PLGA) based drug delivery system in Türkiye

Abstract

Some of the most well-engineered and produced biomaterials are polyesters based on polyglycolic acid (PGA), polylactic acid (PLA), and their copolymers, polylactic acid co-glycolic acid (PLGA). In controlled release systems, PLGA is the most extensively used and popular polymer. Because of its biodegradability, biocompatibility, and favorable release kinetics, but also because of the reliability of protein delivery issues, this synthetic polymer has been found to be very successful. PLGA is approved in various human drug delivery systems by EMA and FDA. In this review, first, PLGA and historical development, usage, physico-chemical structure, drug release properties, degredation specifications, solubility, crystallinity, thermal stability, release properties, types of PLGA will be mentioned. In the last stage of the review, studies conducted in Türkiye are included. In conclusion, we believe that this review is a resource for researchers doing research with PLGA.

Keywords

• PLGA
• Drug Delivery Systems
• Drug Carrier
• Nanotechnology

References

1. Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM. Polymeric systems for controlled drug release. Chem Rev. 1999;99(11):3181-3198. https://doi.org/10.1021/cr940351u
2. Özakar E. Etkin Madde Yüklü PLGA Nanopartiküllerinin Hazırlanması ve in vitro Değerlendirilmesi [master’s thesis]. Erzurum: Atatürk Üniversitesi Sağlık Bilimleri Enstitüsü; 2014.
3. Tabatabaei Mirakabad FS, Nejati-Koshki K, Akbarzadeh A, et al. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15(2):517-535. https://doi.org/10.7314/apjcp.2014.15.2.517
4. Erden N, Çelebi N. Biyolojik olarak parçalanabilen polimer sistemlerin peptit ve proteinlere uygulanması: Sürekli etki sağlayan laktid/glikolid mikroküreleri. FABAD J Pharm Sci. 1993;18:161-171.
5. Hines DJ, Kaplan DL. Poly(lactic-co-glycolic) acid-controlled-release systems: experimental and modeling insights. Crit Rev Ther Drug Carrier Syst. 2013;30(3):257-276. https://doi.org/10.1615/critrevtherdrugcarriersyst.2013006475
6. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-522. https://doi.org/10.1016/j.jconrel.2012.01.043
7. Avgoustakis K. Polylactic-Co-Glycolic Acid (PLGA). In: Wnek GE, Bowlin GL, editors. Encyclopedia of Biomaterials and Biomedical Engineering. CRC Press; 2008. p. 2291-2301.
8. Herrero-Vanrell R, Molina-Martinez IT. PLA and PLGA microparticles for intravitreal drug delivery: an overview. J Drug Deliv Sci Technol. 2007;17(1):11-17. https://doi.org/10.1016/S1773-2247(07)50002-X

9. Sarkar S, Lee GY, Wong JY, Desai TA. Development and characterization of a porous micro-patterned scaffold for vascular tissue engineering applications. Biomaterials. 2006;27(27):4775-4782. https://doi.org/10.1016/j.biomaterials.2006.04.038
10. Hwang CM, Khademhosseini A, Park Y, Sun K, Lee SH. Microfluidic chip-based fabrication of PLGA microfiber scaffolds for tissue engineering. Langmuir. 2008;24(13):6845-6851. https://doi.org/10.1021/la800253b
11. Katas H, Cevher E, Alpar HO. Preparation of polyethyleneimine incorporated poly (d, l-lactide-co-glycolide) nanoparticles by spontaneous emulsion diffusion method for small interfering RNA delivery. Int J Pharm. 2009;369(1-2):144-154. https://doi.org/10.1016/j.ijpharm.2008.10.012
12. Cui W, Bei J, Wang S, et al. Preparation and evaluation of poly(-lactide-coglycolide) (PLGA) microbubbles as a contrast agent for myocardial contrast echocardiography. J Biomed Mater Res B Appl Biomater. 2005;73(1):171-178. https://doi.org/10.1002/jbm.b.30189
13. Eskandari Z, Kazdal F, Bahadori F, Ebrahimi N. Quality-by-design model in optimization of PEG-PLGA nano micelles for targeted cancer therapy. J Drug Deliv Sci Technol. 2018;48:393-402. https://doi.org/10.1016/j.jddst.2018.10.009
14. Sahin A, Esendagli G, Yerlikaya F, Caban-Toktas S, Yoyen-Ermis D, Horzum U, Aktas Y, Khan M, Couvreur P, Capan Y. A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles’ characteristics and efficacy of intracellular delivery. Artif Cells Nanomed Biotechnol. 2017;45(8):1657-1664. https://doi.org/10.1080/21691401.2016.1276924
15. Holy CE, Dang SM, Davies JE, Shoichet MS. In vitro degradation of a novel poly(lactide-co-glycolide) 75/25 foam. Biomaterials. 1999;20(13):1177-1185. https://doi.org/10.1016/s0142-9612(98)00256-7
16. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials. 2000;21(23):2475-90. https://doi.org/10.1016/s0142-9612(00)00115-0
17. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377-1397. https://doi.org/10.3390/polym3031377
18. Amann LC, Gandal MJ, Lin R, Liang Y, Siegel SJ. In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. Pharm Res. 2010;27(8):1730-1737. https://doi.org/10.1007/s11095-010-0152-4
19. Crotts G, Park TG. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. J Microencapsul. 1998;15(6):699-713. https://doi.org/10.3109/02652049809008253
20. Öztürk AA, Martin-Banderas L, Cayero-Otero MD, Yenilmez E, Yazan Y. New approach to hypertension treatment: carvediol-loaded PLGA nanoparticles, preparation, in vitro characterization and gastrointestinal stability. Lat Am J Pharm. 2018;37(9):1730-1741.
21. Lu L, Peter SJ, Lyman MD, et al. In vitro and in vivo degradation of porous poly(DL-lactic-co-glycolic acid) foams. Biomaterials. 2000;21(18):1837-1845. https://doi.org/10.1016/s0142-9612(00)00047-8
22. Schliecker G, Schmidt C, Fuchs S, Wombacher R, Kissel T. Hydrolytic degradation of poly(lactide-co-glycolide) films: effect of oligomers on degradation rate and crystallinity. Int J Pharm. 2003;266(1-2):39-49. https://doi.org/10.1016/s0378-5173(03)00379-x
23. Grizzi I, Garreau H, Li S, Vert M. Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence. Biomaterials. 1995;16(4):305-311. https://doi.org/10.1016/0142-9612(95)93258-f
24. In Pyo Park P, Jonnalagadda S. Predictors of glass transition in the biodegradable poly-lactide and poly-lactide-co-glycolide polymers. J Appl Polym Sci. 2006;100(3):1983-1987. https://doi.org/10.1002/app.22135
25. Fredenberg S, Wahlgren M, Reslow M, Axelsson A. The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems-a review. Int J Pharm. 2011;415(1-2):34-52. https://doi.org/10.1016/j.ijpharm.2011.05.049
26. Bozkir A, Saka OM. Formulation and investigation of 5-FU nanoparticles with factorial design-based studies. Farmaco. 2005;60(10):840-846. https://doi.org/10.1016/j.farmac.2005.06.016
27. Cirpanli Y. Kamptotesin İçeren Polimerik ve Oligosakkarit Bazlı Nanopartiküler Formülasyonların Geliştirilmesi ve in vitro-in vivo Değerlendirilmesi [dissertation]. Ankara: Hacettepe Üniversitesi Sağlık Bilimleri Enstitüsü; 2009.
28. Kilic AC, Capan Y, Vural I, et al. Preparation and characterization of PLGA nanospheres for the targeted delivery of NR2B-specific antisense oligonucleotides to the NMDA receptors in the brain. J Microencapsul. 2005;22(6):633-641. https://doi.org/10.1080/02652040500162766
29. Eroğlu H, Haidar MK, Nemutlu E, et al. Dual release behavior of atorvastatin and alpha-lipoic acid from PLGA microspheres for the combination therapy in peripheral nerve injury. J Drug Deliv Sci Technol. 2017;39:455-466. https://doi.org/10.1016/j.jddst.2017.04.028
30. Özcan I, Azizoğlu E, Senyiğit T, Özyazici M, Özer Ö. Comparison of PLGA and lecithin/chitosan nanoparticles for dermal targeting of betamethasone valerate. J Drug Target. 2013;21(6):542-550. https://doi.org/10.3109/1061186X.2013.769106
31. Sinani G, Sessevmez M, Koray Gök M, et al. Nasal vaccination with poly(β-amino ester)-poly(d,l-lactide-co-glycolide) hybrid nanoparticles. Int J Pharm. 2017;529(1-2):1-14. https://doi.org/10.1016/j.ijpharm.2017.06.053
32. Öztürk AA, Yenilmez E, Özarda MG. Clarithromycin-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles for oral administration: Effect of polymer molecular weight and surface modification with chitosan on formulation, nanoparticle characterization and antibacterial effects. Polymers (Basel). 2019;11(10):1632. https://doi.org/10.3390/polym11101632
33. Orunoğlu M, Kaffashi A, Pehlivan SB, et al. Effects of curcumin-loaded PLGA nanoparticles on the RG2 rat glioma model. Materials Science and Engineering: C. 2017;78:32-38.
34. Rençber S, Aydın Köse F, Karavana SY. Dexamethasone loaded PLGA nanoparticles for potential local treatment of oral precancerous lesions. Pharm Dev Technol. 2020;25(2):149-158. https://doi.org/10.1080/10837450.2019.1673407
35. Öztürk AA, Banderas LM, Otero MDC, Yenilmez E, Şenel B, Yazan Y. Dexketoprofen trometamol-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles: Preparation, in vitro characterization and cyctotoxity. Tropical J Pharm Res. 2019;18(1):1-11. https://doi.org/10.4314/tjpr.v18i1.1
36. Tanrıverdi ST, Suat B, Azizoğlu E, Köse FA. In-vitro evaluation of dexpanthenol-loaded nanofiber mats for wound healing. Tropical J Pharm Res. 2018;17(3):387-394. https://doi.org/10.4314/tjpr.v17i3.1
37. Tunçay M. Diklofenak Sodyum İçeren Mikrokürelerin Biyolojik Parçalanabilen Polimerler ile Formülasyonun Geliştirilmesi ve in vitro, in vivo Değerlendirilmesi [master’s thesis]. Ankara: Hacettepe Üniversitesi Sağlık Bilimleri Enstitüsü; 1998.
38. Cetin M, Atila A, Kadioglu Y. Formulation and in vitro characterization of Eudragit® L100 and Eudragit® L100-PLGA nanoparticles containing diclofenac sodium. AAPS PharmSciTech. 2010;11(3):1250-1256. https://doi.org/10.1208/s12249-010-9489-6
39. Demir D. Dosetaksel İçeren Nanopartiküllerin Formülasyonu ve in vitro Değerlendirilmesi [master’s thesis]. Ankara: Hacettepe Üniversitesi Sağlık Bilimleri Enstitüsü; 2013.
40. Tonbul H. Doksorubisin ve elakridar içeren PLGA/silika hibrit nanopartiküllerin formülasyonu ve meme kanserindeki etkinliğinin değerlendirilmesi [dissertation]. Ankara: Hacettepe Üniversitesi Sağlık Bilimleri Enstitüsü; 2019.
41. Esim O, Savaser A, Kurbanoglu S, Ozkan CK, Ozkan SA, Ozkan Y. Development of assay for determination of eletriptan hydrobromide in loaded PLGA nanoparticles. J Pharm Biomed Anal. 2017;142:74-83. https://doi.org/10.1016/j.jpba.2017.05.002
42. Orhan Z, Cevher E, Gül M, et al. Preparation and In vivo evaluation of gelatine implants containing EGF-PLGA microspheres in tendon healing. ACTA Pharm Sci. 2007;49(3):219-229.
43. Çırpanlı Y, Robineau C, Çapan Y, Çalış S. Etodolac loaded poly (lactide-co-glycolide) nanoparticles: formulation and in vitro characterization. Hacettepe Univ J Faculty Pharm. 2009;29(2):105-114.
44. Samati Y, Yüksel N, Tarimci N. Preparation and characterization of poly(D,L-lactic-co-glycolic Acid) microspheres containing flurbiprofen sodium. Drug Deliv. 2006;13(2):105- 11. https://doi.org/10.1080/10717540500313331
45. Şenel B, Öztürk AA. New approaches to tumor therapy with siRNA-decorated and chitosan-modified PLGA nanoparticles. Drug Dev Ind Pharm. 2019;45(11):1835-1848. https://doi.org/10.1080/03639045.2019.1665061
46. Yalcin TE, Ilbasmis-Tamer S, Takka S. Effect of organic solvents on gemcitabine loaded PLGA nanoparticles. FABAD J Pharm Sci. 2017;42(1):15.
47. Yalcin TE, Ilbasmis-Tamer S, Takka S. Development and characterization of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs) using central composite design. Int J Pharm. 2018;548(1):255-262. https://doi.org/10.1016/j.ijpharm.2018.06.063
48. Yildiz A, John E, Özsoy Y, et al. Inhaled extended-release microparticles of heparin elicit improved pulmonary pharmacodynamics against antigen-mediated airway hyper-reactivity and inflammation. J Control Release. 2012;162(2):456-463. https://doi.org/10.1016/j.jconrel.2012.07.008
49. Sahin A, Spiroux F, Guedon I, et al. Using PVA and TPGS as combined emulsifier in nanoprecipitation method improves characteristics and anticancer activity of ibuprofen loaded PLGA nanoparticles. Pharmazie. 2017;72(9):525-528. https://doi.org/10.1691/ph.2017.7015
50. Karal-Yilmaz O, Ozkan A, Akgun E, et al. Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis. J Mater Sci Mater Med. 2013;24(1):147-153. https://doi.org/10.1007/s10856-012-4784-2
51. Devrim B, Bozkır A. Preparation and in vitro evaluation of surface-modified poly (lactide-co-glycolide) microparticles as biodegradable drug carriers for pulmonary peptide and protein delivery. J Microencapsul. 2014;31(4):355-362. https://doi.org/10.3109/02652048.2013.858791
52. Elmaskaya A, Ozturk AA, Buyukkoroglu G, Yenilmez E. Spray-dried ketoprofen lysine-incorporated PLGA nanoparticles; formulation, characterization, evaluation and cytotoxic profile. Indian J Pharm Sci. 2019;81(4):640-650. https://doi.org/10.36468/pharmaceutical-sciences.555
53. Öztürk AA, Kırımlıoğlu GY. Preparation and in vitro of characterization lamivudine loaded nanoparticles prepared by acid or ester terminated PLGA for effective oral antiretroviral therapy. J Res Pharm. 2019;23(5):897-913. https://doi.org/10.35333/jrp.2019.37
54. Sengel-Turk CT, Hascicek C, Dogan AL, Esendagli G, Guc D, Gonul N. Surface modification and evaluation of PLGA nanoparticles: the effects on cellular uptake and cell proliferation on the HT-29 cell line. J Drug Deliv Sci Technol. 2014;24(2):166-172. https://doi.org/10.1016/S1773-2247(14)50027-5
55. Şengel-Türk CT, Hasçiçek C, Dogan AL, Esendagli G, Guc D, Gönül N. Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells. Drug Dev Ind Pharm. 2012;38(9):1107-1116. https://doi.org/10.3109/03639045.2011.641562
56. Sengel C, Hasçiçek C, Gönül N. Design of vitamin E d-α-tocopheryl polyethylene glycol 1000 succinate-emulsified poly (D,L-lactide-co-glycolide) nanoparticles: Influence of duration of ultrasonication energy. J Young Pharm. 2011;3(3):171-175. https://doi.org/10.4103/0975-1483.83754
57. Gundogdu N, Cetin M. Chitosan-poly (lactide-co-glycolide) (CS-PLGA) nanoparticles containing metformin HCl: preparation and in vitro evaluation. Pak J Pharm Sci. 2014;27(6):1923-1929.
58. Orhan Z, Cevher E, Yildiz A, Ahiskali R, Sensoy D, Mülazimoğlu L. Biodegradable microspherical implants containing teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis. Arch Orthop Trauma Surg. 2010;130(1):135-142. https://doi.org/10.1007/s00402-009-0886-9
59. Turk CT, Oz UC, Serim TM, Hascicek C. Formulation and optimization of nonionic surfactants emulsified nimesulide-loaded PLGA-based nanoparticles by design of experiments. AAPS PharmSciTech. 2014;15(1):161-176. https://doi.org/10.1208/s12249-013-0048-9
60. Gungor S, Okyar A, Erturk-Toker S, Baktir G, Ozsoy Y. Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: in vitro/in vivo studies. Pharm Dev Technol. 2010;15(3):258-265. https://doi.org/10.3109/10837450903148257
61. Aygül G, Yerlikaya F, Caban S, Vural İ, Çapan Y. Formulation and in vitro evaluation of paclitaxel loaded nanoparticles. HUJPHARM. 2013;33(1):25-40.
62. Tonbul H, Sahin A, Tavukcuoglu E, Esendagli G, Capan Y. Combination drug delivery with actively-targeted PLGA nanoparticles to overcome multidrug resistance in breast cancer. J Drug Deliv Sci Technol. 2019;54:101380. https://doi.org/10.1016/j.jddst.2019.101380
63. Sahin A, Caban-Toktas S, Tonbul H, Yerlikaya F, Aktas Y, Capan Y. Development of paclitaxel and flurbiprofen co-loaded PLGA nanoparticles: Understanding critical formulation and process parameters using Plackett–Burman design. Istanbul J Pharm. 2019;49(3):161-166. https://doi.org/10.26650/IstanbulJPharm.2019.19036
64. Ozturk K, Fernández Megía E, Novoa Carballal R, et al. Comparative in vitro studies on PBN loaded nanoparticles prepared by biodegradable chitosan, PLGA polymers and their PEGylated block copolymers. J Drug Deliv Sci Technol. 2014;24(2):148-152. https://doi.org/10.1016/S1773-2247(14)50024-X
65. Capan Y, Woo BH, Gebrekidan S, Ahmed S, DeLuca PP. Influence of formulation parameters on the characteristics of poly(D, L-lactide-co-glycolide) microspheres containing poly(L-lysine) complexed plasmid DNA. J Control Release. 1999;60(2-3):279-286. https://doi.org/10.1016/s0168-3659(99)00076-0
66. Devrim B, Bozkir A, Canefe K. Preparation and evaluation of PLGA microparticles as carrier for the pulmonary delivery of rhIL-2 : I. Effects of some formulation parameters on microparticle characteristics. J Microencapsul. 2011;28(6):582-594. https://doi.org/10.3109/02652048.2011.599438
67. Devrim B, Bozkır A, Canefe K. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations. Drug Dev Ind Pharm. 2011;37(11):1376-1386. https://doi.org/10.3109/03639045.2011.576680
68. Cetin M, Aktas MS, Vural I, Ozturk M. Salmon calcitonin-loaded Eudragit® and Eudragit®-PLGA nanoparticles: in vitro and in vivo evaluation. J Microencapsul. 2012;29(2):156-166. https://doi.org/10.3109/02652048.2011.635426
69. Katas H, Chen S, Osamuyimen AA, Cevher E, Oya Alpar H. Effect of preparative variables on small interfering RNA loaded Poly(D,L-lactide-co-glycolide)-chitosan submicron particles prepared by emulsification diffusion method. J Microencapsul. 2008;25(8):541-548. https://doi.org/10.1080/02652040802075567
70. Cevher E, Orhan Z, Sensoy D, et al. Sodium fusidate-poly(D,L-lactide-co-glycolide) microspheres: preparation, characterisation and in vivo evaluation of their effectiveness in the treatment of chronic osteomyelitis. J Microencapsul. 2007;24(6):577-595. https://doi.org/10.1080/02652040701472584
71. Rençber S, Tanrıverdi ST. Terbinafine hydrochloride loaded PLGA nanoparticles for topical administration. Proceedings of the 3rd World Congress on Recent Advances in Nanotechnology (RAN’18). 2018;112:1-6. https://doi.org/10.11159/nddte18.112
72. Sayin B, Calis S. Influence of accelerated storage conditions on the stability of vancomycin-loaded poly (d, l-lactide-co-glycolide) microspheres. FABAD J Pharm Sci. 2004;29:111-116.
73. Ozalp Y, Ozdemir N, Kocagöz S, Hasirci V. Controlled release of vancomycin from biodegradable microcapsules. J Microencapsul. 2001;18(1):89-110. https://doi.org/10.1080/026520401750038638
74. Ozalp Y, Ozdemir N, Hasirci V. Vancomycin release from poly(D,L-lactide) and poly(lactide-co-glycolide) disks. J Microencapsul. 2002;19(1):83-94. https://doi.org/10.1080/02652040110065404
75. Karagoz H, Ulkur E, Kerimoglu O, et al. Vascular endothelial growth factor-loaded poly(lactic-co-glycolic acid) microspheres-induced lateral axonal sprouting into the vein graft bridging two healthy nerves: nerve graft prefabrication using controlled release system. Microsurgery. 2012;32(8):635-641. https://doi.org/10.1002/micr.22016
76. Sipahigil O, Alarçin E, Türkoğlu M, et al. Characterization, cell proliferation and cytotoxicity evaluation of vascular endothelial growth factor loaded poly (lactic-co-glycolic acid) microspheres. Nobel Med. 2012;8(1):77-82.
77. Öğünç Y, Demirel M, Yakar A, İncesu Z. Vincristine and ɛ-viniferine-loaded PLGA-b-PEG nanoparticles: pharmaceutical characteristics, cellular uptake and cytotoxicity. J Microencapsul. 2017;34(1):38-46. https://doi.org/10.1080/02652048.2017.1282549
78. Öztürk AA, Namlı İ, Güleç K, Kıyan HT. Diclofenac sodium loaded PLGA nanoparticles for inflammatory diseases with high anti-inflammatory properties at low dose: Formulation, characterization and in vivo HET-CAM analysis. Microvascular Research. 2020;130:103991. https://doi.org/10.1016/j.mvr.2020.103991
79. Öztürk AA, Yenilmez E, Şenel B, Kıyan HT, Güven UM. Effect of different molecular weight PLGA on flurbiprofen nanoparticles: formulation, characterization, cytotoxicity, and in vivo anti-inflammatory effect by using HET-CAM assay. Drug Development and Industrial Pharmacy. 2020;46(4):682-695. https://doi.org/10.1080/03639045.2020.1755304
80. Elmaskaya A, Ozturk AA, Buyukkoroglu G, Yenilmez E. Spray-dried ketoprofen lysine-incorporated PLGA nanoparticles; formulation, characterization, evaluation and cytotoxic profile. Indian Journal of Pharmaceutical Sciences, 2019;81(4):640-650. 10.36468/pharmaceutical-sciences.555
81. Öztürk AA, Namlı İ, Aygül A. Cefaclor Monohydrate-Loaded Colon-Targeted Nanoparticles for Use in COVID-19 Dependent Coinfections and Intestinal Symptoms: Formulation, Characterization, Release Kinetics, and Antimicrobial Activity. ASSAY and Drug Development Technologies. 2021;19(3):156-175. https://doi.org/10.1089/adt.2020.1014
82. Ekinci M, Öztürk AA, Santos-Oliveira R, İlem-Özdemir D. The use of Lamivudine-loaded PLGA nanoparticles in the diagnosis of lung cancer: Preparation, characterization, radiolabeling with 99mTc and cell binding. Journal of Drug Delivery Science and Technology. 2022;69:103139. https://doi.org/10.1016/j.jddst.2022.103139
83. Öztürk AA. Deksketoprofen trometamol yüklü kontrollü salım gösteren nanoboyutta ilaç taşıyıcı sistem geliştirilmesi ve in Vitro/in vivo değerlendirilmesi [dissertation]. Anadolu Üniversitesi, Sağlık Bilimleri Enstitüsü, Eskişehir, Türkiye; 2019.
84. Öztürk AA, Yenilmez E. Pharmacological and pharmaceutical technological overview for seborrheic dermatitis: A review about topical application and new approaches. ACTA Pharmaceutica Sciencia. 2018;56(4):57-80. https://doi.org/10.23893/1307-2080.APS.05626
85. Güven UM, Öztürk AA, Yenilmez E. Evaluation of carvedilol-loaded Eudragit® nanoparticles. J Res Pharm. 2020;24(1):71-81. https://doi.org/10.35333/jrp.2020.116
86. Öztürk AA, Arpagaus C. Nano Spray-Dried Drugs for Oral Administration: A Review. ASSAY and Drug Development Technologies. 2021;19(7):412-441. https://doi.org/10.1089/adt.2021.053
87. Öztürk AA, Yenilmez E, Arslan R, Şenel B, Yazan Y. Dexketoprofen trometamol loaded solid lipid nanoparticles (SLNs): Formulation, in vitro and in vivo evaluation. J Res Pharm. 2020;24(1):82-99. https://doi.org/10.35333/jrp.2020.114
88. Öztürk AA, Namlı İ, Güleç K, Görgülü Ş. Design of lamivudine loaded nanoparticles for oral application by nano spray drying method: a new approach to use an antiretroviral drug for lung cancer treatment. Combinatorial Chemistry & High Throughput Screening. 2020:23(10):1064-1079. https://doi.org/10.2174/1386207323666200325155020
89. Öztürk AA, Güven U. Cefaclor monohydrate loaded microemulsion formulation for topical application: Characterization with new developed UPLC method and stability study. J Res Pharm. 2019;23(3):426-440. https://doi.org/10.12991/jrp.2019.150
90. Öztürk AA, Gündüz AB, Ozisik O. Supervised machine learning algorithms for evaluation of solid lipid nanoparticles and particle size. Combinatorial Chemistry & High Throughput Screening. 2018;21(9):693-699. https://doi.org/10.2174/1386207322666181218160704
91. Öztürk AA, Güven U, Yenilmez E, Şenel B. Effects of Different Derivatives of Eudragit Polymer on Entrapment Efficiency, In Vitro Dissolution, Release Kinetics and Cell Viability Results on Extended Release Flurbiprofen Loaded Nanomedicines. Lat Am J Pharm. 2018;37(10):1981-1992.
92. Öztürk AA, Martin-Banderas L, Cayero-Otero MD, Yenilmez E, Yazan Y. New approach to hypertension treatment: carvediol-loaded PLGA nanoparticles, preparation, in vitro characterization and gastrointestinal stability. Lat Am J Pharm. 2018;37(9):1730-1741.
93. Öztürk AA, Çınar Nİ, Yenilmez E. Development of nano-sized ketoprofen lysine incorporated Eudragit (R) S100 nanomedicine by double emulsion solvent evaporation and in vitro characterization. J Pharm Pharmacogn Res. 2019;7(1):47-58.